

Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study

This article was originally published [here](#)

Results suggest that Entresto, an essential treatment for HFrEF, not only positively impacts a biomarker shown to be associated with prognosis of clinical outcomes in HFrEF, but also

The post [Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study](#) appeared first on [Pharmaceutical Business review](#).